Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary purpose of this study is to compare the effect of a double dose of a study drug known as insulin peglispro to a double dose of insulin glargine in participants who have type 2 diabetes. Participants will be treated with study insulin daily, in two 4-week study periods. Each participant will receive insulin peglispro during one treatment period and insulin glargine during the other treatment period.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Have type 2 diabetes mellitus (T2DM), based on the World Health Organization (WHO) classification, for ≥1 year.
Use any type of basal insulin (except degludec), including once-or twice-daily human insulin neutral protamine Hagedom (NPH), insulin detemir, or insulin glargine.
Have hemoglobin A1c (HbA1c) levels ≤9.0% according to local laboratory testing at screening.
Have body mass index (BMI) ≤40.0 kilograms/square meter (kg/m^2).
Have been treated with stable doses of insulin for at least 30 days before screening with:
If on metformin, thiazolidinediones (TZDs), sodium glucose co-transporter 2 (SGLT-2) inhibitors, or dipeptidyl peptidase (DPP4) inhibitors, must be on stable doses for the last 30 days.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
68 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal